Catalent announces two appointments to executive leadership team in management realignment
Alessandro Maselli is to become its new Senior Vice President of Global Operations, and Christine Dolan will assume the role of Senior Vice President of Global Product Development.
Catalent Pharma Solutions has announced that Alessandro Maselli is to become its new Senior Vice President of Global Operations, while Christine Dolan will assume the role of Senior Vice President of Global Product Development.
Mr Maselli has extensive operations experience at several global organizations, and previously acted as Vice President Operations for Catalent’s Drug Delivery Solutions business in Europe. Prior to this, he was General Manager of Catalent’s Zydis orally disintegrating tablet facility in Swindon, UK, and held a number of other senior management and operational roles, having joined the organization from Alstom in 2010. Before joining Alstom, Mr Maselli had worked in business management and operations positions for SGS and ABB respectively.
He holds a master’s and bachelor’s degree in engineering from Università degli Studi di Roma 'La Sapienza,' Rome.
Mr Steve Leonard, who previously held the position, has decided to leave the company in early 2017, but will continue in an advisory position until that time, to assist with the transition.
Ms Dolan was appointed Vice President, Global Softgel Operations in November 2013, with responsibility for Catalent’s 11 Softgel manufacturing and development sites, spanning five continents. In this role she had operational responsibility for more than 3,500 employees.
She began her career with Catalent in 2009 in Global Quality, and in 2010 was named General Manager for Catalent’s Woodstock, Illinois, sterile technologies facility. She had previously acted as Vice President of Operations for the Development and Clinical Services Business Unit, with operational responsibilities for five of Catalent’s facilities providing clinical manufacturing, packaging, and analytical development of both large and small molecules. Following Catalent’s acquisition of Aptuit’s clinical trials business in 2011, Ms Dolan was named Vice President and General Manager of Development and Analytical Solutions, which included operations in Kansas City, Missouri, Morrisville, North Carolina, and Swindon, UK. Prior to Catalent, she worked as a microbiologist for Smith & Nephew Solopak, and also Amersham Health and GE Healthcare, where she served in various leadership roles.
Ms Dolan holds a bachelor’s degree in biology from Lenoir-Rhyne College, North Carolina.
“We are confident that both Alessandro and Christine will continue to drive the organization forward and believe that this management realignment will bring value, not only to Catalent as a business, but our customers, and ultimately patients,” commented John Chiminski, Catalent’s President and CEO. He added, “At the same time, it is important to recognize the enormous impact that Steve has made on the company’s transformation and growth since his appointment in 2009. We wish him all the best for the future and will always be appreciative of his professionalism, strategic contribution, energy and insight.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance